Bronstein, Gewirtz & Grossman, LLC Is Investigating Madrigal Pharmaceuticals, Inc. (MDGL) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / November 16, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Madrigal Pharmaceuticals, Inc. ("Madrigal" or "the Company") (NASDAQ:MDGL). Investors who purchased Madrigal securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/madrigal-pharmaceuticals-inc-mdgl-investigation.
Madrigal Investigation Details
On November 3, 2026, Madrigal disclosed in its quarterly report that its former Senior Vice President and Head of Clinical Development, Dr. Michael Charlton, had filed a whistleblower complaint against the Company. According to the complaint, Dr. Charlton repeatedly reported concerns that Madrigal was suppressing adverse liver-injury data, presenting efficacy results that could not be reconciled with source data, and allowing an unblinded board member and major shareholder to control the adjudication of clinical outcomes. Following this news, Madrigal's stock price dropped.
What's Next for Madrigal Investors?
If you are aware of any facts relating to this investigation or purchased Madrigal securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/madrigal-pharmaceuticals-inc-mdgl-investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Madrigal Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Madrigal Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire